ASH

The past few months have been great for small cap bluebird bio Inc (NASDAQ: BLUE), which saw its stock appreciate more than 47.6 percent in the last six months and more than 31 percent in the past month alone, largely helped by the entry of its Gen2 LentiGlobin into the clinic. Benzinga recently...

• ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) CEO Dr. Laurence Cooper believes that the company’s cell programming languages set it apart from other cancer researchers. • The company’s Sleeping Beauty platform allows for T cell modification without the use of a viral...

Thomas Yip of FBR commented in a note on Monday that shares of Geron Corporation (NASDAQ: GERN) are undervalued. Geron's imetelstat's pilot study will be presented during the upcoming American Society of Hematology (ASH) meeting in early December. Yip stated the presentation could "attract...